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We identified a case of breakthrough candidemia in a 25-year-old patient receiving micafungin prophylaxis (50 mg/day). Five
Candida glabrata isolates were obtained from blood cultures and were classified as multidrug-resistant isolates, since all of them
exhibited highMICs for echinocandin and azole drugs. Amutation (S663F) in hot spot 1 of the FKS2 gene was found in all five
isolates. This mutation yielded a 1,3--D-glucan synthase enzyme with highly reduced sensitivities to echinocandin drugs.
In recent years, the epidemiology of candidemia in Latin Amer-ican hospitals has been changing, with a trend toward an in-
crease in the incidence of candidemia due to Candida glabrata, as
documented in recently publishedmulticenter studies (1, 2, 3).C.
glabrata is naturally less susceptible to azoles than other Candida
species (4), and this has led to the expanded use of echinocandins
for fungemia treatment caused by this Candida species (5, 6, 7).
This class of drug is now reported as the first-line therapy for
candidemia in several guidelines of medical societies (5, 6, 7).
Acquired echinocandin resistance among Candida spp. is
largely infrequent. Yet, episodes of invasive infection due to echi-
nocandin-resistant Candida isolates are increasingly being re-
ported in U.S. and European medical centers (8, 9, 10, 11). We
describe one case of C. glabrata breakthrough candidemia docu-
mented in a patient with Burkitt lymphoma and prolonged neu-
tropenia who received antifungal prophylaxis with low doses of
micafungin (50 mg/day) in a tertiary care hospital in Curitiba,
Paraná, Brazil. This is the first documented case of multidrug re-
sistance among clinical strains of C. glabrata from a Latin Ameri-
can medical center.
Case. A 25-year-old man was diagnosed with stage IV adult
sporadic Burkitt lymphoma in November 2011, and due to pro-
found neutropenia, he received fluconazole prophylactically at
doses of 200 mg/day for 20 days (27 November to 16 December),
followed by micafungin at doses of 50 mg/day for 12 days (17
December to 28 December). In January 2012 (3 January), the pa-
tient was admitted for a third round of chemotherapy treatment
with a cyclophosphamide, vincristine, doxorubicin, dexametha-
sone (hyper-CVAD) regimen, having presented with profound
neutropenia since December 2011. Levofloxacin and sulfame-
thoxazole-trimethoprim were initiated as prophylaxis therapy.
Due to prolonged neutropenia, antifungal prophylaxis was re-
started with micafungin at doses of 50 mg/day (posaconazole is not
available in Brazil). At day 12 of hospitalization, the patient de-
veloped feverduring aneutropenicperiod,without adefined focusof
infection, and cefepime treatment was initiated empirically. A blood
culture was collected and revealed growth of Candida (isolate 1),
despite 24 days of exposure to micafungin. Initially, the decision
was made to increase the micafungin dose to 100 mg/day. The
patient continued to have a fever for 6 days after initiation of the
micafungin treatment (100 mg/day), with sequential blood cul-
tures positive for Candida (isolates 2 to 5). Possible infectious foci
for persistent fungemia (endocarditis, hepatosplenic candidiasis, and
fungalmeningitis)were ruledoutby clinical, imaging, and laboratory
tests. Echinocandin resistancewas suspected, and a conventional for-
mulationof amphotericinBwas initiatedwithgoodclinical response.
Blood cultures were negative after 5 days of treatment.
A total of five clinical Candida isolates were obtained from
sequential blood cultures collected during breakthrough candi-
demia that occurred during antifungal prophylaxis withmicafun-
gin (50 mg/day). All isolates tested were identified as Candida
glabrata by internal transcribed spacer (ITS) sequencing, as pre-
viously described by our group (12, 13).
Antifungal susceptibility testing was performed using the
brothmicrodilutionmethod according toClinical and Laboratory
Standards Institute (CLSI) documentM27-A3 (14), using current
CLSI MIC interpretative criteria (CLSI, M27-S4) (15). The anti-
fungal compounds were kindly provided as pure powders by their
manufacturers. All five C. glabrata bloodstream isolates tested ex-
hibited resistance to fluconazole (FLC), voriconazole (VRC), and
all echinocandins. The MIC values for echinocandins were 16- to
33-fold higher than those for the control strain (ATCC 90030).
Table 1 summarizes the MIC values obtained for the five C.
glabrata isolates for the six antifungal agents tested.
DNA sequencing analyses of the two hot spot (HS) regions of
the drug target genes FKS1 and FKS2 were performed on the five
C. glabrata clinical isolates, as previously described (16). The two
HS regions of the FKS1 gene corresponded to nucleotides (nt)
1873 to 1902 (amino acids [aa] 625 to 633) and nt 4018 to 4041 (aa
1340 to 1347) of the published strain C. glabrata ATCC 90030
(DNA Data Bank of Japan [DDBJ] accession no. HM366440.1),
and the twoHS regions of the FKS2 gene corresponded to nt 1975
to 2001 (aa 659 to 667) andnt 4122 to 4143 (aa 1374 to 1381) of the
published strain C. glabrata ATCC 90030 (DDBJ accession no.
HM366442.1). The sequencing of the HS regions of the FKS genes
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revealed only a nonsynonymous mutation in HS1 in the FKS2
gene, which led to an S663F amino acid substitution (Table 1).
We performed an in vitro glucan synthase inhibition assay, as
previously described (17, 18, 19). The echinocandin inhibition
parameter 50% inhibitory concentration (IC50) was determined
for the wild-type strain (C. glabrata ATCC 90030) and the 8622A
clinical isolate (Table 1). The fks mutant enzyme extracted from
the clinical isolate showed significantly higher IC50 values than did
the corresponding enzyme isolated from the wild-type strain (58-,
43-, and4,000-fold on average for anidulafungin [ANF], caspo-
fungin [CSF], and micafungin [MCF], respectively) (Table 1 and
Fig. 1). These results confirm that the point mutation S663F en-
coded in the FKS2 gene of C. glabrata yielded a 1,3--D-glucan
synthase enzymewith highly reduced sensitivities to echinocandin
drugs, resulting in elevated MICs with a strong potential for clin-
ical failure. In the present investigation, a patient with Burkitt
lymphoma and severe neutropenia that was expected to persist for
a longer period of time was subjected to antifungal prophylaxis
withmicafungin at a dosage of 50mg daily. The patient developed
C. glabrata breakthrough candidemia after 19 and 24 days of ex-
posure to fluconazole and micafungin, respectively. In vitro anti-
fungal susceptibility testing confirmed the resistance to flucona-
zole, voriconazole, and all echinocandins.
The epidemiologic impact of using an echinocandin for anti-
fungal prophylaxis in neutropenic patients in terms of promoting
the development of multidrug-resistant Candida isolates remains
unclear, but it is concerning. ProminentC. glabrata echinocandin
resistance has recently been reported by Alexander et al. (8) and
Pfaller et al. (9), whose studies suggested significant emergence of
multidrug resistance over time to both azoles and echinocandins
in C. glabrata isolates.
As echinocandins are more frequently used for the treatment
of invasive candidiasis, sporadic cases of echinocandin break-
through candidemia associated with nonsusceptible Candida iso-
lates and treatment failure have been reported (10, 11, 19). In the
present study, all five C. glabrata isolates recovered from sequen-
tial blood cultures collected during prophylaxis therapy with mi-
cafungin showed increases in the echinocandin MIC values, and
all of them showed a point mutation in HS1 in the FKS2 gene that
led to a S663F amino acid substitution, which has been previously
described as being involved in treatment failure and echinocandin
resistance in C. glabrata isolates (20). Notably, other studies have
shown that a point mutation in the same position of the FKS2
gene, though with a different amino acid substitution (S663P), is
the most frequently observed mutation related to echinocandin
resistance in C. glabrata isolates (21, 22). It is important to note
that in our case, in accordance with previous publications, the long-
termechinocandinexposure (24days) resulted in thedevelopmentof
FKS gene mutations and echinocandin resistance (10). On the other
hand, one case of rapid echinocandin resistance in C. glabrata was
reported by Lewis et al. (23) in a patient without previous or pro-
longed echinocandin exposure (8 days of treatment).
Ourfindings emphasize that thewidespreaduse of echinocandins
may increase the occurrence of echinocandin resistance, especially
whenusing lowdoses, as in the present case inwhich theneutropenic
patient was exposed to 50 mg daily. In this scenario, the use of echi-
nocandin as prophylactic therapy should be recommended cau-
tiously in patients with a high risk of candidemia development, now
that previous exposure to echinocandins has been clearly recognized
as a risk factor for the development of resistance.
Nucleotide sequence accession numbers. The sequences gen-
erated in this study have been deposited in the GenBank (NCBI)
TABLE 1 In vitro activities of six antifungal agents and GS inhibition profiles for echinocandin drugs against five C. glabrata isolates harboring FKS
mutations
Strain/mutation FKS2 hot spot genotype
MIC (mg/liter) for: IC50 (ng/ml) for:
AMB FLC VRC ANF CSF MCF ANF CSF MCF
ATCC 90030 FKS1/FKS1 (wild type) 0.25 4 0.03 0.06 0.03 0.03 46.1 29.7 15.29
8622 A fks1/fks1 (S663F) 0.25 64.0 4.0 1.0 1.0 0.5 2,655 1,263 61,760
8622 B fks1/fks1 (S663F) 0.25 64.0 4.0 1.0 1.0 0.5 NDa ND ND
8622 C fks1/fks1 (S663F) 0.25 64.0 4.0 1.0 1.0 0.5 ND ND ND
8622 D fks1/fks1 (S663F) 0.25 64.0 4.0 1.0 1.0 0.5 ND ND ND
8622 E fks1/fks1 (S663F) 0.25 64.0 4.0 1.0 1.0 0.5 ND ND ND
a ND, not determined.
FIG 1 Echinocandin inhibition profiles for product-entrapped 1,3--D-glucan synthase enzyme complexes assessed by the incorporation of [3H]glucose into
radiolabeled product. Titration curves are shown for anidulafungin (ANF), caspofungin (CSF), and micafungin (MCF) for the wild type and clinical isolate
8622A of C. glabrata.
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database under accessionnumbersKF211452,KF211447,KF211442,
KF211437, KF211456, KF211448, KF211438, KF211443, KF211455,
KF211449, KF211444, KF211439, KF211454, KF211450, KF211445,
KF211440, KF211453, KF211451, KF211446, KF211441, KF305827,
KF305828, KF305829, KF305830, and KF305831.
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